logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Dong-Wan Kim

seoul national university
H指数:72
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

NeoCOAST-2研究中可切除肺癌的循环肿瘤DNA清除与预后

Nature
IF48.5
2026-10-250
PRE
Lara McGrath; Gozde Kar; Laura Bonanno; Florian Guisier; Amelia Insa; Moishe Liberman; Olivier Bylicki; Lorenzo Livi; Thomas Egenod; Romain Corre; Dong-Wan Kim; Maria Rosario Garcia Campelo; Mariano Provencio Pulla; Byoung Yong Shim; Giulio Metro; Jaafar Bennouna; Agata A. Bielska; Alula R. Yohannes; Joanna Shaju; Yun He; Adam Dowson; Italia Grenga; Jonathan Spicer; Patrick M. Forde; Tina Cascone
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

Reptrectinib治疗NTRK融合阳性的晚期实体瘤: 1/2期试验

Nature Medicine
IF50
2026-02-040
OA
Benjamin Besse; Jessica J. Lin; Lyudmila Bazhenova; Koichi Goto; Adrianus Johannes de Langen; Dong-Wan Kim; Jürgen Wolf; Christoph Springfeld; Sanjay Popat; Darren W. T. Lim; Misako Nagasaka; Jung Yong Hong; Christina S. Baik; Alice Hervieu; Victor Moreno; Nong Yang; Kanthi Kollengode; Haisu Yang; Yuanfang Xu; Christophe Y. Calvet; Yong Yuan; Amy B. Hammell; Alexander Drilon; Benjamin J. Solomon
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer

MAGELLAN方案B1和B3臂：在治疗初治转移性非小细胞肺癌患者中，比较度伐利尤单抗联合化疗与联合化疗并联合奥雷oclumab的疗效。

Lung Cancer
IF4.4
2025-11-070
PRE
Byoung Chul Cho; Chaiyut Charoentum; Dong-Wan Kim; Cheng-Ta Yang; Rafal Dziadziuszko; Sarayut Lucien Geater; Helen Mann; Banafsheh Afshar-Imani; Pavlo Lyfar; James Chih-Hsin Yang; Sandip Pravin Patel
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and leptomeningeal metastases: The KCSG LU 21-01, LAZARUS study

拉泽替尼联合培美曲塞治疗表皮生长因子受体突变阳性非小细胞肺癌合并软脑膜转移的II期研究：KCSG LU 21-01、LAZARUS研究

Lung Cancer
IF4.4
2025-11-010
PRE
Hyun-Ae Jung; Tae Min Kim; Hye Ryun Kim; Chang Gon Kim; Hee Kyung Ahn; Youngjoo Lee; Yu Jung Kim; Miso Kim; Jeonghwan Youk; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Dong-Wan Kim; Myung-Ju Ahn; Bhumsuk Keam
\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study

阿来替尼对比克唑替尼用于初治ALK阳性晚期非小细胞肺癌：III期ALEX研究最终总生存期分析

Annals of Oncology
IF65.4
2025-10-170
OAAI
S. Peters; R. Camidge; R. Dziadziuszko; S. Gadgeel; A.T. Shaw; D-W. Kim; M. Pérol; D.R. Rosell; P. Cheema; D.Wan-Teck Lim; J.J. Lin; N. Pavlakis; J.S. Ahn; L. Zhang; V. Henschel; A.A. Higgerson; V. McNally; I. Rooney; A. Scalori; V. Smoljanovic; T. Mok
Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer

最终分析结果和患者报告结局来自DESTINY-Lung02——一项关于曲妥珠单抗德鲁替康在HER2突变型转移性非小细胞肺癌患者中的剂量盲法、随机、II期研究

Journal of Thoracic Oncology
IF20.8
2025-07-300
PREAI
Pasi A. Jänne; Yasushi Goto; Toshio Kubo; Kiichiro Ninomiya; Sang-We Kim; David Planchard; Myung-Ju Ahn; Egbert Smit; Adrianus Johannes de Langen; Maurice Pérol; Elvire Pons-Tostivint; Silvia Novello; Hidetoshi Hayashi; Junichi Shimizu; Dong-Wan Kim; Kaline Pereira; Fu-Chih Cheng; Ayumi Taguchi; Yingkai Cheng; Kyle Dunton; Ahmed Ali; Koichi Goto
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
Nature Medicine
IF50
2025-05-310
OAAI
Tina Cascone; Laura Bonanno; Florian Guisier; Amelia Insa; Moishe Liberman; Olivier Bylicki; Lorenzo Livi; Thomas Egenod; Romain Corre; Dong-Wan Kim; Maria Rosario Garcia Campelo; Mariano Provencio Pulla; Byoung Yong Shim; Giulio Metro; Jaafar Bennouna; Agata A. Bielska; Alula R. Yohannes; Yun He; Adam Dowson; Gozde Kar; Lara McGrath; Rakesh Kumar; Italia Grenga; Jonathan Spicer; Patrick M. Forde
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study

亚洲晚期ALK阳性NSCLC患者中，劳拉替尼一线治疗与克唑替尼的对比：CROWN研究五年结果

Journal of Thoracic Oncology
IF20.8
2025-02-280
OAAI
Yi-Long Wu; Hye Ryun Kim; Ross A. Soo; Qing Zhou; Hiroaki Akamatsu; Gee-Chen Chang; Chao-Hua Chiu; Hidetoshi Hayashi; Sang-We Kim; Yasushi Goto; Terufumi Kato; Jianying Zhou; Victor Ho-Fun Lee; Makoto Nishio; Baohui Han; Dong-Wan Kim; Shun Lu; Anna Polli; Jean-François Martini; Francesca Toffalorio; Tony Mok
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study

通过分子改变选择的实体瘤患者的sitratinib: Ib期研究的结果

FUTURE ONCOLOGY
IF2.6
2024-11-080
OAAI
Bazhenova, Lyudmila; Kim, Dong-Wan; Cho, Byoung Chul; Goel, Sanjay; Heist, Rebecca; Werner, Theresa L.; Eaton, Keith D.; Wang, Judy S.; Pant, Shubham; Adkins, Douglas R.; Blakely, Collin M.; Yan, Xiaohong; Neuteboom, Saskia; Christensen, James G.; Chao, Richard; Bauer, Todd
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study

1/2期LASER201研究中使用拉泽替尼治疗的EGFR T790M-positive晚期非小细胞肺癌患者的更新的总生存期和ctDNA分析

BMC MEDICINE
IF8.3
2024-10-080
OAAI
Han, Ji-Youn; Ahn, Myung-Ju; Lee, Ki Hyeong; Lee, Yun-Gyoo; Kim, Dong-Wan; Min, Young Joo; Kim, Sang-We; Cho, Eun Kyung; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Sung Sook; Lee, Na Mi; Jang, Hyun Woo; Han, Heewon; Park, Hyejoo; Lee, Jieon; Cho, Byoung Chul
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer

简明语言总结: 劳拉替尼与克唑替尼在非小细胞肺癌中的CROWN研究的5年结果

FUTURE ONCOLOGY
IF2.6
2024-10-030
OAAI
Solomon, Benjamin J.; Liu, Geoffrey; Felip, Enriqueta; Mok, Tony S. K.; Soo, Ross A.; Mazieres, Julien; Shaw, Alice T.; de Marinis, Filippo; Goto, Yasushi; Wu, Yi-Long; Kim, Dong-Wan; Martini, Jean-Francois; Messina, Rossella; Paolini, Jolanda; Polli, Anna; Thomaidou, Despina; Toffalorio, Francesca; Bauer, Todd M.

研究方向

暂未获取到该数据
D
Dae Seog Heo
H 指数:77论文数:662被引数:2.3万
T
Tae Min Kim
H 指数:69论文数:757被引数:2.1万
B
Bhumsuk Keam
H 指数:63论文数:697被引数:1.7万
M
Miso Kim
H 指数:33论文数:190被引数:5,054
S
Se‐Hoon Lee
H 指数:87论文数:1,134被引数:3.2万
J
Jeonghwan Youk
H 指数:18论文数:118被引数:1,910
S
Sang‐We Kim
H 指数:57论文数:372被引数:2.1万
Y
Yi‐Long Wu
H 指数:135论文数:2,242被引数:11.2万
B
Byoung Chul Cho
H 指数:106论文数:1,592被引数:7.0万
K
Keunchil Park
H 指数:113论文数:958被引数:7.3万